Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration

A Randomized, Double-Masked, Multi-Center Phase I Study of 6 Months Duration to Assess the Safety and Tolerability of Intravenous ACZ885 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.

Inclusion criteria:

• Male or female ≥ 50 years old, with aged related macular degeneration
• Patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Exclusion criteria:

• Active intraocular inflammation or ocular infection in the study eye
• Eye disease that may result in visual loss during the study
• Chronic therapy with topical, local or systemic corticosteroids.
• Pregnant or nursing (lactating) women.